Clinical Trials in Canada / NCT07924007
Starting soon
Not applicable
Cardiopulmonary Complications of Electronic Cigarettes
NCT07924007 · tracked via the Priya Life Science Canada tracker
Condition(s) studied
Electronic Cigarette UseCannabis Use
Investigational drug(s) / intervention(s)
Lower body positive and negative pressureExercise
Lower body positive and negative pressure: Primary outcomes will be assessed during graded lower body positive pressure (+10, +20, +30 mmHg) and negative pressure (-15, -30, -45, -60 mmHg).
Exercise: Primary outcomes will be examined at rest and at exercise intensities between \~20%-100% of their V̇O2max.
Study summary
The study aims to look at whether changes in the blood vessels of the lungs are related to how well electronic cigarette users tolerate exercise. It also aims to investigate whether increasing blood flow to the lungs can improve the reduced ability of E-CIG users' lungs to transfer oxygen into the bloodstream.
Eligibility
Inclusion Criteria:
Adolescent Cohort:
1. Participants aged ≥12 and \<18 years
2. Non-smoking and Non-E-CIG Use: \<100 lifetime cigarettes and \< 200 E-CIG puffs
3. E-CIG Use Only: currently using E-CIGs every day or some days
4. Cannabis Use: cannabis smoking history of \> 1 joint-year
5. Combined E-CIG and Cannabis Use: adolescents who meet both #3 and #4
Adult Cohort:
1. Participants aged 18-40 years
2. Non-smoking and Non-E-CIG Use: \<100 lifetime cigarettes and \< 200 E-CIG puffs
3. E-CIG Use Only: currently using E-CIGs every day or some days
4. Cannabis Use: cannabis smoking history of \> 1 joint-year
5. Combined E-CIG and Cannabis Use: adults who meet both #3 and #4
Exclusion Criteria:
1. Contraindication to pulmonary function testing (i.e. recent thoracic or abdominal surgery, aneurysms, cardiovascular instability)
2. Unable to provide informed consent
3. Currently undergoing treatment for lung cancer
4. Cigarette smoking in the past 6 months
5. Physician-diagnosed chronic lung disease (e.g. cystic fibrosis, asthma, primary ciliary dyskinesia, bronchopulmonary dysplasia) (adolescent arm only)
6. Self-reported premature infancy, referring to individuals who were born premature (born before the 37th week of pregnancy). Previous literature and work in our lab have shown that lung development is blunted in these individuals, and we are therefore excluding those born prematurely so that underdeveloped lungs do not impact the findings of the present study.
7. Pregnancy. To confirm this, women not using contraception will be given a pregnancy test prior to starting the study. Pregnancy presents additional complications and may confound the results of the study; therefore, pregnant women will be excluded.
Primary outcome measure(s)
- Diffusing capacity of carbon monoxide (DLCO) — Time Frame: Days 2 and 3. Measurements will be taken during each stage of intervention, after a minimum of 2 minutes from the onset of each stage.
Diffusing capacity of carbon monoxide (DLCO) in selected exercise intensities, lower-body pressures, and body positions. DLCO is measured using the single-breath dual gas pulmonary diffusing capacity for nitric oxide and carbon monoxide technique. - Capillary blood volume (Vc) — Time Frame: Days 2 and 3. Measurements will be taken during each stage of intervention, after a minimum of 2 minutes from the onset of each stage.
Capillary blood volume is a component of DLCO and is measured with the single-breath dual gas pulmonary diffusing capacity for nitric oxide and carbon monoxide technique. - Membrane diffusing capacity (Dm) — Time Frame: Days 2 and 3. Measurements will be taken during each stage of intervention, after a minimum of 2 minutes from the onset of each stage.
Membrane diffusing capacity is a component of DLCO and is measured with the single-breath dual gas pulmonary diffusing capacity for nitric oxide and carbon monoxide technique.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Clinical Physiology Laboratory | Edmonton | Alberta |
More University of Alberta trials in Canada
Attrition in Pediatric Obesity Management
Active, not recruiting
PET Perfusion Imaging Techniques and Comparing Them to CT Perfusion Imaging in Stroke
Active, not recruiting
Antibiotic Prophylaxis for Bladder Botox
Recruiting
Other trials for the same condition
Vaping Adverse Lung and Heart Events Cohort
Recruiting
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07924007 on ClinicalTrials.gov ↗ ← All trials in Canada